Small Molecule Active Pharmaceutical Ingredient Market Report

Europe Small Molecule Active Pharmaceutical Ingredient Market Size, Status and Forecast 2014-2026

  • POSTDATE：Jun 19, 2020
  • PAGES：223
  • REPORT CODE：GMM561974
  • REPORT SUMMARY
  • TABLE OF CONTENTS

  • The Small Molecule Active Pharmaceutical Ingredient market was valued at XX.0 Million US$ in 2018 and is projected to reach XX.0 Million US$ by 2026, at a CAGR (Compound Annual Growth Rate) of 4.3% during the forecast period. Focusing on the Europe market, this report analyzes the specific consumption structure, such as types and end users. In order to present the status of the circulation of this product in different Europe countries, this report covers top export and import countries to confirm the potential markets. Leading countries such as Germany, UK, France, Italy, Spain, Poland, Russia, Switzerland, Turkey, Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden), Benelux (Belgium, Netherlands, and Luxembourg), Baltic States (Estonia, Latvia, and Lithuania) and other countries, the market status and consumption potential of these countries are covered in the research, providing valuable opinions of strategic adjustments for existing groups and new entrants.

    The Snapshot of Europe Small Molecule Active Pharmaceutical Ingredient Market Segmentations:

    By Player:

    • GlaxoSmithKline

    • Roche

    • Bristol-Myers Squibb

    • Bachem Holding AG

    • Teva Pharmaceuticals

    • Boehringer Ingelheim GmbH

    • BASF SE

    • Johnson & Johnson

    • Johnson Matthey

    • Cambrex Corporation

    • Novartis AG,

    • PCAS

    • AstraZeneca

    • Pfizer

    • Siegfried Holding AG

    By Type:

    • Standard API

    • High Potency API

    By End-User:

    • Brake calipers

    • Commercial vehicle

    • Passenger vehicle

    By Region:

    • Germany

    • UK

    • France

    • Italy

    • Spain

    • Poland

    • Russia

    • Switzerland

    • Turkey

    • Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden)

      • Denmark

      • Finland

      • Norway

      • Sweden

      • Iceland

    • Benelux (Belgium, Netherlands, and Luxembourg)

      • Belgium

      • Netherlands

      • Luxembourg

    • Baltic States (Estonia, Latvia, and Lithuania)

      • Estonia

      • Latvia

      • Lithuania

  • Table of Contents

    1 Report Overview

    • 1.1 Product Definition and Scope

    • 1.2 PEST (Political, Economic, Social and Technological) Analysis of Small Molecule Active Pharmaceutical Ingredient Market

    • 1.3 Market Segment by Type

    • 1.3.1 Europe Small Molecule Active Pharmaceutical Ingredient Market Size and Growth Rate of Standard API from 2014 to 2026

    • 1.3.2 Europe Small Molecule Active Pharmaceutical Ingredient Market Size and Growth Rate of High Potency API from 2014 to 2026

    • 1.4 Market Segment by Application

    • 1.4.1 Europe Small Molecule Active Pharmaceutical Ingredient Market Size and Growth Rate of Brake calipers from 2014 to 2026

    • 1.4.2 Europe Small Molecule Active Pharmaceutical Ingredient Market Size and Growth Rate of Commercial vehicle from 2014 to 2026

    • 1.4.3 Europe Small Molecule Active Pharmaceutical Ingredient Market Size and Growth Rate of Passenger vehicle from 2014 to 2026

    • 1.5 Market Segment by Regions

      • 1.5.1 Germany Small Molecule Active Pharmaceutical Ingredient Market Size and Growth Rate from 2014 to 2026

      • 1.5.2 UK Small Molecule Active Pharmaceutical Ingredient Market Size and Growth Rate from 2014 to 2026

      • 1.5.3 France Small Molecule Active Pharmaceutical Ingredient Market Size and Growth Rate from 2014 to 2026

      • 1.5.4 Italy Small Molecule Active Pharmaceutical Ingredient Market Size and Growth Rate from 2014 to 2026

      • 1.5.5 Spain Small Molecule Active Pharmaceutical Ingredient Market Size and Growth Rate from 2014 to 2026

      • 1.5.6 Poland Small Molecule Active Pharmaceutical Ingredient Market Size and Growth Rate from 2014 to 2026

      • 1.5.7 Russia Small Molecule Active Pharmaceutical Ingredient Market Size and Growth Rate from 2014 to 2026

      • 1.5.8 Switzerland Small Molecule Active Pharmaceutical Ingredient Market Size and Growth Rate from 2014 to 2026

      • 1.5.9 Turkey Small Molecule Active Pharmaceutical Ingredient Market Size and Growth Rate from 2014 to 2026

      • 1.5.10 Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Small Molecule Active Pharmaceutical Ingredient Market Size and Growth Rate from 2014 to 2026

      • 1.5.11 Benelux (Belgium, Netherlands, and Luxembourg) Small Molecule Active Pharmaceutical Ingredient Market Size and Growth Rate from 2014 to 2026

      • 1.5.12 Baltic States (Estonia, Latvia, and Lithuania) Small Molecule Active Pharmaceutical Ingredient Market Size and Growth Rate from 2014 to 2026

    2 Market Trends and Competitive Landscape

    • 2.1 Market Trends and Dynamics

      • 2.1.1 Market Challenges and Restraints

      • 2.1.2 Market Opportunities and Potentials

      • 2.1.3 Mergers and Acquisitions

    • 2.2 Competitive Landscape Analysis

      • 2.2.1 Industrial Concentration Analysis

      • 2.2.2 Porter's Five Forces Analysis of the Industry

      • 2.2.3 SWOT Analysis for New Entrants

    3 Segmentation of Small Molecule Active Pharmaceutical Ingredient Market by Types

    • 3.1 Products Development Trends of Different Types

    • 3.2 Commercial Products Types of Major Venders

    • 3.3 Competitive Landscape Analysis of Different Types

    • 3.4 Market Size of Small Molecule Active Pharmaceutical Ingredient by Major Types

      • 3.4.1 Market Size and Growth Rate of Standard API

      • 3.4.2 Market Size and Growth Rate of High Potency API

    4 Segmentation of Small Molecule Active Pharmaceutical Ingredient Market by End-Users

    • 4.1 Downstream Client Analysis by End-Users

    • 4.2 Competitive Landscape Analysis of Different End-Users

    • 4.3 Market Potential Analysis of Different End-Users

    • 4.4 Market Size of Small Molecule Active Pharmaceutical Ingredient by Major End-Users

      • 4.4.1 Market Size and Growth Rate of Brake calipers for Construction

      • 4.4.2 Market Size and Growth Rate of Commercial vehicle for Construction

      • 4.4.3 Market Size and Growth Rate of Passenger vehicle for Construction

    5 Market Analysis by Major Regions

    • 5.1 Europe Small Molecule Active Pharmaceutical Ingredient Production Analysis by Top Regions

    • 5.2 Europe Small Molecule Active Pharmaceutical Ingredient Consumption Analysis by Top Regions

    • 5.3 Europe Small Molecule Active Pharmaceutical Ingredient Production, Import, Consumption and Export Analysis by Regions

      • 5.3.1 Germany Small Molecule Active Pharmaceutical Ingredient Production, Import, Consumption and Export Analysis

      • 5.3.2 UK Small Molecule Active Pharmaceutical Ingredient Production, Import, Consumption and Export Analysis

      • 5.3.3 France Small Molecule Active Pharmaceutical Ingredient Production, Import, Consumption and Export Analysis

      • 5.3.4 Italy Small Molecule Active Pharmaceutical Ingredient Production, Import, Consumption and Export Analysis

      • 5.3.5 Spain Small Molecule Active Pharmaceutical Ingredient Production, Import, Consumption and Export Analysis

      • 5.3.6 Poland Small Molecule Active Pharmaceutical Ingredient Production, Import, Consumption and Export Analysis

      • 5.3.7 Russia Small Molecule Active Pharmaceutical Ingredient Production, Import, Consumption and Export Analysis

      • 5.3.8 Switzerland Small Molecule Active Pharmaceutical Ingredient Production, Import, Consumption and Export Analysis

      • 5.3.9 Turkey Small Molecule Active Pharmaceutical Ingredient Production, Import, Consumption and Export Analysis

      • 5.3.10 Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Small Molecule Active Pharmaceutical Ingredient Production, Import, Consumption and Export Analysis

      • 5.3.11 Benelux (Belgium, Netherlands, and Luxembourg) Small Molecule Active Pharmaceutical Ingredient Production, Import, Consumption and Export Analysis

      • 5.3.12 Baltic States (Estonia, Latvia, and Lithuania) Small Molecule Active Pharmaceutical Ingredient Production, Import, Consumption and Export Analysis

    6 Product Circulation of Small Molecule Active Pharmaceutical Ingredient Market among Top Countries

    • 6.1 Top 5 Export Countries in Small Molecule Active Pharmaceutical Ingredient Market from 2014 to 2019

      • 6.1.1 Top 5 Export Countries’ Export Value Analysis in Small Molecule Active Pharmaceutical Ingredient Market from 2014 to 2019

      • 6.1.2 Top 5 Export Countries’ Export Volume Analysis in Small Molecule Active Pharmaceutical Ingredient Market from 2014 to 2019

    • 6.2 Top 5 Import Countries in Small Molecule Active Pharmaceutical Ingredient Market from 2014 to 2019

      • 6.2.1 Top 5 Import Countries’ Import Value Analysis in Small Molecule Active Pharmaceutical Ingredient Market from 2014 to 2019

      • 6.2.2 Top 5 Import Countries’ Import Volume Analysis in Small Molecule Active Pharmaceutical Ingredient Market from 2014 to 2019

    • 6.3 Emerging Top 3 Export Countries Analysis

    • 6.4 Emerging Top 3 Import Countries Analysis

    7. Germany Small Molecule Active Pharmaceutical Ingredient Landscape Analysis

    • 7.1 Germany Small Molecule Active Pharmaceutical Ingredient Landscape Analysis by Major Types

    • 7.2 Germany Small Molecule Active Pharmaceutical Ingredient Landscape Analysis by Major End-Users

    8. UK Small Molecule Active Pharmaceutical Ingredient Landscape Analysis

    • 8.1 UK Small Molecule Active Pharmaceutical Ingredient Landscape Analysis by Major Types

    • 8.2 UK Small Molecule Active Pharmaceutical Ingredient Landscape Analysis by Major End-Users

    9. France Small Molecule Active Pharmaceutical Ingredient Landscape Analysis

    • 9.1 France Small Molecule Active Pharmaceutical Ingredient Landscape Analysis by Major Types

    • 9.2 France Small Molecule Active Pharmaceutical Ingredient Landscape Analysis by Major End-Users

    10. Italy Small Molecule Active Pharmaceutical Ingredient Landscape Analysis

    • 10.1 Italy Small Molecule Active Pharmaceutical Ingredient Landscape Analysis by Major Types

    • 10.2 Italy Small Molecule Active Pharmaceutical Ingredient Landscape Analysis by Major End-Users

    11. Spain Small Molecule Active Pharmaceutical Ingredient Landscape Analysis

    • 11.1 Spain Small Molecule Active Pharmaceutical Ingredient Landscape Analysis by Major Types

    • 11.2 Spain Small Molecule Active Pharmaceutical Ingredient Landscape Analysis by Major End-Users

    12. Poland Small Molecule Active Pharmaceutical Ingredient Landscape Analysis

    • 12.1 Poland Small Molecule Active Pharmaceutical Ingredient Landscape Analysis by Major Types

    • 12.2 Poland Small Molecule Active Pharmaceutical Ingredient Landscape Analysis by Major End-Users

    13. Russia Small Molecule Active Pharmaceutical Ingredient Landscape Analysis

    • 13.1 Russia Small Molecule Active Pharmaceutical Ingredient Landscape Analysis by Major Types

    • 13.2 Russia Small Molecule Active Pharmaceutical Ingredient Landscape Analysis by Major End-Users

    14. Switzerland Small Molecule Active Pharmaceutical Ingredient Landscape Analysis

    • 14.1 Switzerland Small Molecule Active Pharmaceutical Ingredient Landscape Analysis by Major Types

    • 14.2 Switzerland Small Molecule Active Pharmaceutical Ingredient Landscape Analysis by Major End-Users

    15. Turkey Small Molecule Active Pharmaceutical Ingredient Landscape Analysis

    • 15.1 Turkey Small Molecule Active Pharmaceutical Ingredient Landscape Analysis by Major Types

    • 15.2 Turkey Small Molecule Active Pharmaceutical Ingredient Landscape Analysis by Major End-Users

    16. Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Small Molecule Active Pharmaceutical Ingredient Landscape Analysis

    • 16.1 Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Small Molecule Active Pharmaceutical Ingredient Landscape Analysis by Major Types

    • 16.2 Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Small Molecule Active Pharmaceutical Ingredient Landscape Analysis by Major End-Users

    • 16.3 Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Small Molecule Active Pharmaceutical Ingredient Landscape Analysis by Top Countries

      • 16.3.1 Denmark Small Molecule Active Pharmaceutical Ingredient Market Volume and Growth Rate

      • 16.3.2 Finland Small Molecule Active Pharmaceutical Ingredient Market Volume and Growth Rate

      • 16.3.3 Norway Small Molecule Active Pharmaceutical Ingredient Market Volume and Growth Rate

      • 16.3.4 Sweden Small Molecule Active Pharmaceutical Ingredient Market Volume and Growth Rate

      • 16.3.6 Iceland Small Molecule Active Pharmaceutical Ingredient Market Volume and Growth Rate

    17 Benelux (Belgium, Netherlands, and Luxembourg) Small Molecule Active Pharmaceutical Ingredient Landscape Analysis

    • 17.1 Benelux (Belgium, Netherlands, and Luxembourg) Small Molecule Active Pharmaceutical Ingredient Landscape Analysis by Major Types

    • 17.2 Benelux (Belgium, Netherlands, and Luxembourg) Small Molecule Active Pharmaceutical Ingredient Landscape Analysis by Major End-Users

    • 17.3 Benelux (Belgium, Netherlands, and Luxembourg) Small Molecule Active Pharmaceutical Ingredient Landscape Analysis by Top Countries

      • 17.3.1 Belgium Small Molecule Active Pharmaceutical Ingredient Market Volume and Growth Rate

      • 17.3.2 Netherlands Small Molecule Active Pharmaceutical Ingredient Market Volume and Growth Rate

      • 17.3.3 Luxembourg Small Molecule Active Pharmaceutical Ingredient Market Volume and Growth Rate

    18 Baltic States (Estonia, Latvia, and Lithuania) Small Molecule Active Pharmaceutical Ingredient Landscape Analysis

    • 18.1 Baltic States (Estonia, Latvia, and Lithuania) Small Molecule Active Pharmaceutical Ingredient Landscape Analysis by Major Types

    • 18.2 Baltic States (Estonia, Latvia, and Lithuania) Small Molecule Active Pharmaceutical Ingredient Landscape Analysis by Major End-Users

    • 18.3 Baltic States (Estonia, Latvia, and Lithuania) Small Molecule Active Pharmaceutical Ingredient Landscape Analysis by Top Countries

      • 18.3.1 Estonia Small Molecule Active Pharmaceutical Ingredient Market Volume and Growth Rate

      • 18.3.2 Latvia Small Molecule Active Pharmaceutical Ingredient Market Volume and Growth Rate

      • 18.3.3 Lithuania Small Molecule Active Pharmaceutical Ingredient Market Volume and Growth Rate

    19 Major Players Profiles

    • 19.1 GlaxoSmithKline

      • 19.1.1 GlaxoSmithKline Company Profile and Development Status

      • 19.1.2 Market Performance

      • 19.1.3 Product and Service Introduction

    • 19.2 Roche

      • 19.2.1 Roche Company Profile and Development Status

      • 19.2.2 Market Performance

      • 19.2.3 Product and Service Introduction

    • 19.3 Bristol-Myers Squibb

      • 19.3.1 Bristol-Myers Squibb Company Profile and Development Status

      • 19.3.2 Market Performance

      • 19.3.3 Product and Service Introduction

    • 19.4 Bachem Holding AG

      • 19.4.1 Bachem Holding AG Company Profile and Development Status

      • 19.4.2 Market Performance

      • 19.4.3 Product and Service Introduction

    • 19.5 Teva Pharmaceuticals

      • 19.5.1 Teva Pharmaceuticals Company Profile and Development Status

      • 19.5.2 Market Performance

      • 19.5.3 Product and Service Introduction

    • 19.6 Boehringer Ingelheim GmbH

      • 19.6.1 Boehringer Ingelheim GmbH Company Profile and Development Status

      • 19.6.2 Market Performance

      • 19.6.3 Product and Service Introduction

    • 19.7 BASF SE

      • 19.7.1 BASF SE Company Profile and Development Status

      • 19.7.2 Market Performance

      • 19.7.3 Product and Service Introduction

    • 19.8 Johnson & Johnson

      • 19.8.1 Johnson & Johnson Company Profile and Development Status

      • 19.8.2 Market Performance

      • 19.8.3 Product and Service Introduction

    • 19.9 Johnson Matthey

      • 19.9.1 Johnson Matthey Company Profile and Development Status

      • 19.9.2 Market Performance

      • 19.9.3 Product and Service Introduction

    • 19.10 Cambrex Corporation

      • 19.10.1 Cambrex Corporation Company Profile and Development Status

      • 19.10.2 Market Performance

      • 19.10.3 Product and Service Introduction

    • 19.11 Novartis AG,

      • 19.11.1 Novartis AG, Company Profile and Development Status

      • 19.11.2 Market Performance

      • 19.11.3 Product and Service Introduction

    • 19.12 PCAS

      • 19.12.1 PCAS Company Profile and Development Status

      • 19.12.2 Market Performance

      • 19.12.3 Product and Service Introduction

    • 19.13 AstraZeneca

      • 19.13.1 AstraZeneca Company Profile and Development Status

      • 19.13.2 Market Performance

      • 19.13.3 Product and Service Introduction

    • 19.14 Pfizer

      • 19.14.1 Pfizer Company Profile and Development Status

      • 19.14.2 Market Performance

      • 19.14.3 Product and Service Introduction

    • 19.15 Siegfried Holding AG

      • 19.15.1 Siegfried Holding AG Company Profile and Development Status

      • 19.15.2 Market Performance

      • 19.15.3 Product and Service Introduction

    The List of Tables and Figures (Totals 97 Figures and 161 Tables)

    • Figure Product Picture

    • Figure Small Molecule Active Pharmaceutical Ingredient Market Size and Growth Rate of Standard API Market, 2015 - 2026 (USD Million)

    • Figure Small Molecule Active Pharmaceutical Ingredient Market Size and Growth Rate of High Potency API Market, 2015 - 2026 (USD Million)

    • Figure Small Molecule Active Pharmaceutical Ingredient Market Size and Growth Rate of Brake calipers from 2014 to 2026

    • Figure Small Molecule Active Pharmaceutical Ingredient Market Size and Growth Rate of Commercial vehicle from 2014 to 2026

    • Figure Small Molecule Active Pharmaceutical Ingredient Market Size and Growth Rate of Passenger vehicle from 2014 to 2026

    • Figure Germany Small Molecule Active Pharmaceutical Ingredient Market Size and Growth Rate from 2014 to 2026

    • Figure UK Small Molecule Active Pharmaceutical Ingredient Market Size and Growth Rate from 2014 to 2026

    • Figure France Small Molecule Active Pharmaceutical Ingredient Market Size and Growth Rate from 2014 to 2026

    • Figure Italy Small Molecule Active Pharmaceutical Ingredient Market Size and Growth Rate from 2014 to 2026

    • Figure Spain Small Molecule Active Pharmaceutical Ingredient Market Size and Growth Rate from 2014 to 2026

    • Figure Poland Small Molecule Active Pharmaceutical Ingredient Market Size and Growth Rate from 2014 to 2026

    • Figure Russia Small Molecule Active Pharmaceutical Ingredient Market Size and Growth Rate from 2014 to 2026

    • Figure Switzerland Small Molecule Active Pharmaceutical Ingredient Market Size and Growth Rate from 2014 to 2026

    • Figure Turkey Small Molecule Active Pharmaceutical Ingredient Market Size and Growth Rate from 2014 to 2026

    • Figure Canada Small Molecule Active Pharmaceutical Ingredient Market Size and Growth Rate from 2014 to 2026

    • Figure Mexico Small Molecule Active Pharmaceutical Ingredient Market Size and Growth Rate from 2014 to 2026

    • Figure Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Small Molecule Active Pharmaceutical Ingredient Market Size and Growth Rate from 2014 to 2026

    • Figure Denmark Small Molecule Active Pharmaceutical Ingredient Market Size and Growth Rate from 2014 to 2026

    • Figure Finland Small Molecule Active Pharmaceutical Ingredient Market Size and Growth Rate from 2014 to 2026

    • Figure Norway Small Molecule Active Pharmaceutical Ingredient Market Size and Growth Rate from 2014 to 2026

    • Figure Sweden Small Molecule Active Pharmaceutical Ingredient Market Size and Growth Rate from 2014 to 2026

    • Figure Iceland Small Molecule Active Pharmaceutical Ingredient Market Size and Growth Rate from 2014 to 2026

    • Figure Benelux (Belgium, Netherlands, and Luxembourg) Small Molecule Active Pharmaceutical Ingredient Market Size and Growth Rate from 2014 to 2026

    • Figure Belgium Small Molecule Active Pharmaceutical Ingredient Market Size and Growth Rate from 2014 to 2026

    • Figure Netherlands Small Molecule Active Pharmaceutical Ingredient Market Size and Growth Rate from 2014 to 2026

    • Figure Luxembourg Small Molecule Active Pharmaceutical Ingredient Market Size and Growth Rate from 2014 to 2026

    • Figure Baltic States (Estonia, Latvia, and Lithuania) Small Molecule Active Pharmaceutical Ingredient Market Size and Growth Rate from 2014 to 2026

    • Figure Estonia Small Molecule Active Pharmaceutical Ingredient Market Size and Growth Rate from 2014 to 2026

    • Figure Latvia Small Molecule Active Pharmaceutical Ingredient Market Size and Growth Rate from 2014 to 2026

    • Figure Lithuania Small Molecule Active Pharmaceutical Ingredient Market Size and Growth Rate from 2014 to 2026

    • Figure Development Trends and Industry Dynamics of Small Molecule Active Pharmaceutical Ingredient Industry

    • Figure Market Challenges and Restraints

    • Figure Market Opportunities and Potentials

    • Table Mergers and Acquisition

    • Figure Market Share of TOP 6 Players from 2014 to 2019

    • Figure Porter's Five Forces Analysis

    • Figure New Entrant SWOT Analysis

    • Table Specifications of Different Types of Small Molecule Active Pharmaceutical Ingredient

    • Figure Development Trends of Different Types

    • Table Commercial Products Types of Major Vendors

    • Figure Competitive Landscape Analysis of Different Types

    • Table Consumption of Small Molecule Active Pharmaceutical Ingredient by Different Types from 2014 to 2026

    • Table Consumption Share of Small Molecule Active Pharmaceutical Ingredient by Different Types from 2014 to 2026

    • Figure Small Molecule Active Pharmaceutical Ingredient Market Size and Growth Rate of Standard API Market, 2015 - 2026 (USD Million)

    • Figure Small Molecule Active Pharmaceutical Ingredient Market Size and Growth Rate of High Potency API Market, 2015 - 2026 (USD Million)

    • Table Downstream Client Analysis by End-Users

    • Figure Competitive Landscape Analysis of Different End-Users

    • Table Market Potential Analysis of Different End-Users

    • Table Consumption of Small Molecule Active Pharmaceutical Ingredient by Different End-Users from 2014 to 2026

    • Table Consumption Share of Small Molecule Active Pharmaceutical Ingredient by Different End-Users from 2014 to 2026

    • Figure Small Molecule Active Pharmaceutical Ingredient Market Size and Growth Rate of Brake calipers from 2014 to 2026

    • Figure Small Molecule Active Pharmaceutical Ingredient Market Size and Growth Rate of Commercial vehicle from 2014 to 2026

    • Figure Small Molecule Active Pharmaceutical Ingredient Market Size and Growth Rate of Passenger vehicle from 2014 to 2026

    • Table Europe Small Molecule Active Pharmaceutical Ingredient Production by Major Regions

    • Table Europe Small Molecule Active Pharmaceutical Ingredient Production Share by Major Regions

    • Figure Europe Small Molecule Active Pharmaceutical Ingredient Production Share by Major Countries and Regions in 2014

    • Table Europe Small Molecule Active Pharmaceutical Ingredient Consumption by Major Regions

    • Table Europe Small Molecule Active Pharmaceutical Ingredient Consumption Share by Major Regions

    • Table Germany Small Molecule Active Pharmaceutical Ingredient Production, Import, Consumption and Export Analysis

    • Table UK Small Molecule Active Pharmaceutical Ingredient Production, Import, Consumption and Export Analysis

    • Table France Small Molecule Active Pharmaceutical Ingredient Production, Import, Consumption and Export Analysis

    • Table Italy Small Molecule Active Pharmaceutical Ingredient Production, Import, Consumption and Export Analysis

    • Table Spain Small Molecule Active Pharmaceutical Ingredient Production, Import, Consumption and Export Analysis

    • Table Poland Small Molecule Active Pharmaceutical Ingredient Production, Import, Consumption and Export Analysis

    • Table Russia Small Molecule Active Pharmaceutical Ingredient Production, Import, Consumption and Export Analysis

    • Table Switzerland Small Molecule Active Pharmaceutical Ingredient Production, Import, Consumption and Export Analysis

    • Table Turkey Small Molecule Active Pharmaceutical Ingredient Production, Import, Consumption and Export Analysis

    • Table Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Small Molecule Active Pharmaceutical Ingredient Production, Import, Consumption and Export Analysis

    • Table Benelux (Belgium, Netherlands, and Luxembourg) Small Molecule Active Pharmaceutical Ingredient Production, Import, Consumption and Export Analysis

    • Table Baltic States (Estonia, Latvia, and Lithuania) Small Molecule Active Pharmaceutical Ingredient Production, Import, Consumption and Export Analysis

    • Table Top 5 Export Countries' Export Value Analysis in Small Molecule Active Pharmaceutical Ingredient Market from 2014 to 2019

    • Table Top 5 Export Countries' Export Volume Analysis in Small Molecule Active Pharmaceutical Ingredient Market from 2014 to 2019

    • Table Top 5 Import Countries' Import Value Analysis in Small Molecule Active Pharmaceutical Ingredient Market from 2014 to 2019

    • Table Top 5 Import Countries' Import Volume Analysis in Small Molecule Active Pharmaceutical Ingredient Market from 2014 to 2019

    • Figure Emerging Top 3 Export Countries Analysis

    • Figure Emerging Top 3 Import Countries Analysis

    • Table Germany Small Molecule Active Pharmaceutical Ingredient Consumption by Types from 2014 to 2026

    • Table Germany Small Molecule Active Pharmaceutical Ingredient Consumption Share by Types from 2014 to 2026

    • Table Germany Small Molecule Active Pharmaceutical Ingredient Consumption by End-Users from 2014 to 2026

    • Table Germany Small Molecule Active Pharmaceutical Ingredient Consumption Share by End-Users from 2014 to 2026

    • Table UK Small Molecule Active Pharmaceutical Ingredient Consumption by Types from 2014 to 2026

    • Table UK Small Molecule Active Pharmaceutical Ingredient Consumption Share by Types from 2014 to 2026

    • Table UK Small Molecule Active Pharmaceutical Ingredient Consumption by End-Users from 2014 to 2026

    • Table UK Small Molecule Active Pharmaceutical Ingredient Consumption Share by End-Users from 2014 to 2026

    • Table France Small Molecule Active Pharmaceutical Ingredient Consumption by Types from 2014 to 2026

    • Table France Small Molecule Active Pharmaceutical Ingredient Consumption Share by Types from 2014 to 2026

    • Table France Small Molecule Active Pharmaceutical Ingredient Consumption by End-Users from 2014 to 2026

    • Table France Small Molecule Active Pharmaceutical Ingredient Consumption Share by End-Users from 2014 to 2026

    • Table Italy Small Molecule Active Pharmaceutical Ingredient Consumption by Types from 2014 to 2026

    • Table Italy Small Molecule Active Pharmaceutical Ingredient Consumption Share by Types from 2014 to 2026

    • Table Italy Small Molecule Active Pharmaceutical Ingredient Consumption by End-Users from 2014 to 2026

    • Table Italy Small Molecule Active Pharmaceutical Ingredient Consumption Share by End-Users from 2014 to 2026

    • Table Spain Small Molecule Active Pharmaceutical Ingredient Consumption by Types from 2014 to 2026

    • Table Spain Small Molecule Active Pharmaceutical Ingredient Consumption Share by Types from 2014 to 2026

    • Table Spain Small Molecule Active Pharmaceutical Ingredient Consumption by End-Users from 2014 to 2026

    • Table Spain Small Molecule Active Pharmaceutical Ingredient Consumption Share by End-Users from 2014 to 2026

    • Table Poland Small Molecule Active Pharmaceutical Ingredient Consumption by Types from 2014 to 2026

    • Table Poland Small Molecule Active Pharmaceutical Ingredient Consumption Share by Types from 2014 to 2026

    • Table Poland Small Molecule Active Pharmaceutical Ingredient Consumption by End-Users from 2014 to 2026

    • Table Poland Small Molecule Active Pharmaceutical Ingredient Consumption Share by End-Users from 2014 to 2026

    • Table Russia Small Molecule Active Pharmaceutical Ingredient Consumption by Types from 2014 to 2026

    • Table Russia Small Molecule Active Pharmaceutical Ingredient Consumption Share by Types from 2014 to 2026

    • Table Russia Small Molecule Active Pharmaceutical Ingredient Consumption by End-Users from 2014 to 2026

    • Table Russia Small Molecule Active Pharmaceutical Ingredient Consumption Share by End-Users from 2014 to 2026

    • Table Switzerland Small Molecule Active Pharmaceutical Ingredient Consumption by Types from 2014 to 2026

    • Table Switzerland Small Molecule Active Pharmaceutical Ingredient Consumption Share by Types from 2014 to 2026

    • Table Switzerland Small Molecule Active Pharmaceutical Ingredient Consumption by End-Users from 2014 to 2026

    • Table Switzerland Small Molecule Active Pharmaceutical Ingredient Consumption Share by End-Users from 2014 to 2026

    • Table Turkey Small Molecule Active Pharmaceutical Ingredient Consumption by Types from 2014 to 2026

    • Table Turkey Small Molecule Active Pharmaceutical Ingredient Consumption Share by Types from 2014 to 2026

    • Table Turkey Small Molecule Active Pharmaceutical Ingredient Consumption by End-Users from 2014 to 2026

    • Table Turkey Small Molecule Active Pharmaceutical Ingredient Consumption Share by End-Users from 2014 to 2026

    • Table Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Small Molecule Active Pharmaceutical Ingredient Consumption by Types from 2014 to 2026

    • Table Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Small Molecule Active Pharmaceutical Ingredient Consumption Share by Types from 2014 to 2026

    • Table Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Small Molecule Active Pharmaceutical Ingredient Consumption by End-Users from 2014 to 2026

    • Table Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Small Molecule Active Pharmaceutical Ingredient Consumption Share by End-Users from 2014 to 2026

    • Table Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Small Molecule Active Pharmaceutical Ingredient Consumption by Major Countries from 2014 to 2026

    • Table Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Small Molecule Active Pharmaceutical Ingredient Consumption Share by Major Countries from 2014 to 2026

    • Figure Denmark Small Molecule Active Pharmaceutical Ingredient Market Volume and Growth Rate from 2014 to 2026

    • Figure Finland Small Molecule Active Pharmaceutical Ingredient Market Volume and Growth Rate from 2014 to 2026

    • Figure Norway Small Molecule Active Pharmaceutical Ingredient Market Volume and Growth Rate from 2014 to 2026

    • Figure Sweden Small Molecule Active Pharmaceutical Ingredient Market Volume and Growth Rate from 2014 to 2026

    • Figure Iceland Small Molecule Active Pharmaceutical Ingredient Market Volume and Growth Rate from 2014 to 2026

    • Table Benelux (Belgium, Netherlands, and Luxembourg) Small Molecule Active Pharmaceutical Ingredient Consumption by Types from 2014 to 2026

    • Table Benelux (Belgium, Netherlands, and Luxembourg) Small Molecule Active Pharmaceutical Ingredient Consumption Share by Types from 2014 to 2026

    • Table Benelux (Belgium, Netherlands, and Luxembourg) Small Molecule Active Pharmaceutical Ingredient Consumption by End-Users from 2014 to 2026

    • Table Benelux (Belgium, Netherlands, and Luxembourg) Small Molecule Active Pharmaceutical Ingredient Consumption Share by End-Users from 2014 to 2026

    • Table Benelux (Belgium, Netherlands, and Luxembourg) Small Molecule Active Pharmaceutical Ingredient Consumption by Major Countries from 2014 to 2026

    • Table Benelux (Belgium, Netherlands, and Luxembourg) Small Molecule Active Pharmaceutical Ingredient Consumption Share by Major Countries from 2014 to 2026

    • Figure Belgium Small Molecule Active Pharmaceutical Ingredient Market Volume and Growth Rate from 2014 to 2026

    • Figure Netherlands Small Molecule Active Pharmaceutical Ingredient Market Volume and Growth Rate from 2014 to 2026

    • Figure Luxembourg Small Molecule Active Pharmaceutical Ingredient Market Volume and Growth Rate from 2014 to 2026

    • Table Baltic States (Estonia, Latvia, and Lithuania) Small Molecule Active Pharmaceutical Ingredient Consumption by Types from 2014 to 2026

    • Table Baltic States (Estonia, Latvia, and Lithuania) Small Molecule Active Pharmaceutical Ingredient Consumption Share by Types from 2014 to 2026

    • Table Baltic States (Estonia, Latvia, and Lithuania) Small Molecule Active Pharmaceutical Ingredient Consumption by End-Users from 2014 to 2026

    • Table Baltic States (Estonia, Latvia, and Lithuania) Small Molecule Active Pharmaceutical Ingredient Consumption Share by End-Users from 2014 to 2026

    • Table Baltic States (Estonia, Latvia, and Lithuania) Small Molecule Active Pharmaceutical Ingredient Consumption by Major Countries from 2014 to 2026

    • Table Baltic States (Estonia, Latvia, and Lithuania) Small Molecule Active Pharmaceutical Ingredient Consumption Share by Major Countries from 2014 to 2026

    • Figure Estonia Small Molecule Active Pharmaceutical Ingredient Market Volume and Growth Rate from 2014 to 2026

    • Figure Latvia Small Molecule Active Pharmaceutical Ingredient Market Volume and Growth Rate from 2014 to 2026

    • Figure Lithuania Countries Small Molecule Active Pharmaceutical Ingredient Market Volume and Growth Rate from 2014 to 2026

    • Table GlaxoSmithKline Profiles

    • Table GlaxoSmithKline Production, Value, Price, Gross Margin 2014-2019

    • Table GlaxoSmithKline Product benchmarking

    • Table GlaxoSmithKline Strategic initiatives

    • Table GlaxoSmithKline SWOT analysis

    • Table Roche Profiles

    • Table Roche Production, Value, Price, Gross Margin 2014-2019

    • Table Roche Product benchmarking

    • Table Roche Strategic initiatives

    • Table Roche SWOT analysis

    • Table Bristol-Myers Squibb Profiles

    • Table Bristol-Myers Squibb Production, Value, Price, Gross Margin 2014-2019

    • Table Bristol-Myers Squibb Product benchmarking

    • Table Bristol-Myers Squibb Strategic initiatives

    • Table Bristol-Myers Squibb SWOT analysis

    • Table Bachem Holding AG Profiles

    • Table Bachem Holding AG Production, Value, Price, Gross Margin 2014-2019

    • Table Bachem Holding AG Product benchmarking

    • Table Bachem Holding AG Strategic initiatives

    • Table Bachem Holding AG SWOT analysis

    • Table Teva Pharmaceuticals Profiles

    • Table Teva Pharmaceuticals Production, Value, Price, Gross Margin 2014-2019

    • Table Teva Pharmaceuticals Product benchmarking

    • Table Teva Pharmaceuticals Strategic initiatives

    • Table Teva Pharmaceuticals SWOT analysis

    • Table Boehringer Ingelheim GmbH Profiles

    • Table Boehringer Ingelheim GmbH Production, Value, Price, Gross Margin 2014-2019

    • Table Boehringer Ingelheim GmbH Product benchmarking

    • Table Boehringer Ingelheim GmbH Strategic initiatives

    • Table Boehringer Ingelheim GmbH SWOT analysis

    • Table BASF SE Profiles

    • Table BASF SE Production, Value, Price, Gross Margin 2014-2019

    • Table BASF SE Product benchmarking

    • Table BASF SE Strategic initiatives

    • Table BASF SE SWOT analysis

    • Table Johnson & Johnson Profiles

    • Table Johnson & Johnson Production, Value, Price, Gross Margin 2014-2019

    • Table Johnson & Johnson Product benchmarking

    • Table Johnson & Johnson Strategic initiatives

    • Table Johnson & Johnson SWOT analysis

    • Table Johnson Matthey Profiles

    • Table Johnson Matthey Production, Value, Price, Gross Margin 2014-2019

    • Table Johnson Matthey Product benchmarking

    • Table Johnson Matthey Strategic initiatives

    • Table Johnson Matthey SWOT analysis

    • Table Cambrex Corporation Profiles

    • Table Cambrex Corporation Production, Value, Price, Gross Margin 2014-2019

    • Table Cambrex Corporation Product benchmarking

    • Table Cambrex Corporation Strategic initiatives

    • Table Cambrex Corporation SWOT analysis

    • Table Novartis AG, Profiles

    • Table Novartis AG, Production, Value, Price, Gross Margin 2014-2019

    • Table Novartis AG, Product benchmarking

    • Table Novartis AG, Strategic initiatives

    • Table Novartis AG, SWOT analysis

    • Table PCAS Profiles

    • Table PCAS Production, Value, Price, Gross Margin 2014-2019

    • Table PCAS Product benchmarking

    • Table PCAS Strategic initiatives

    • Table PCAS SWOT analysis

    • Table AstraZeneca Profiles

    • Table AstraZeneca Production, Value, Price, Gross Margin 2014-2019

    • Table AstraZeneca Product benchmarking

    • Table AstraZeneca Strategic initiatives

    • Table AstraZeneca SWOT analysis

    • Table Pfizer Profiles

    • Table Pfizer Production, Value, Price, Gross Margin 2014-2019

    • Table Pfizer Product benchmarking

    • Table Pfizer Strategic initiatives

    • Table Pfizer SWOT analysis

    • Table Siegfried Holding AG Profiles

    • Table Siegfried Holding AG Production, Value, Price, Gross Margin 2014-2019

    • Table Siegfried Holding AG Product benchmarking

    • Table Siegfried Holding AG Strategic initiatives

    • Table Siegfried Holding AG SWOT analysis

Report Version Choose

Report

BUY NOW

Our Customers

Beyond grateful for the confidence and support from all partners and customers.A win-win situation is our ultimate pursuit.

Beyond Consulting, Future is Feasible

We provide more professional and intelligent market reports to complement your business decisions.

CONTACT US